Differential Analysis of Rat Bone Marrow by Flow Cytometry

Saad, Alaa; Palm, M.; Widell, Susanne; Reiland, Sven

doi:10.1007/s005800070016

Cited by 41 publications

(39 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This method is tedious and labor intensive, with several hundred cells being counted per slide. Evidence suggests that flow cytometric analysis of rodent bone marrow can identify major hematopoietic subsets and reveal hematologic abnormalities [31][32][33][34]. Therefore, flow cytometric bone marrow differential analysis was investigated as a replacement to the manual cytologic technique.…”

Section: Mouse Bone Marrow Assessmentmentioning

confidence: 99%

Flow Cytometry in Preclinical Toxicology/Safety Assessment

McFarland¹,

Harkins

2010

Flow Cytometry in Drug Discovery and Development

View full text Add to dashboard Cite

Section: Mouse Bone Marrow Assessmentmentioning

confidence: 99%

Flow Cytometry in Preclinical Toxicology/Safety Assessment

McFarland¹,

Harkins

2010

Flow Cytometry in Drug Discovery and Development

View full text Add to dashboard Cite

“…Femoral bone marrow suspension from rats on days 1 and 15 of the recovery period was maintained in IMDM prior to flow cytometry analysis with the FACS Calibur (Becton Dickinson Biosciences, Oxford, UK). Flow cytometry acquisition was carried out within twelve hours of sampling according to the method of Saad et al (2001) for bone marrow myeloid, erythroid, and lymphoid precursor percentages, and myeloid:erythroid (M:E) ratios.…”

Section: Hematology and Bone Marrow Smearsmentioning

confidence: 99%

“…Bone marrow samples were acquired using the gating strategy of Saad et al (2001) and data saved for 10,000 nucleated cells. Data generated were expressed as percentage of nucleated cells acquired.…”

Section: Hematology and Bone Marrow Smearsmentioning

confidence: 99%

Time-course Study of the Immunotoxic Effects of the Anticancer Drug Chlorambucil in the Rat

et al. 2009

View full text Add to dashboard Cite

In 2005, the International conference on harmonization (ICH) recommended that all new human pharmaceuticals be tested for unintended immunomodulatory potential via a tiered approach. Included in this approach is a semiquantitative description of changes in the separate compartments of lymphoid tissue (also called enhanced histopathology). Chlorambucil was administered to Hanover Wistar rats at regular time points, followed by a treatment-free (recovery) period. Groups of treated and control animals were sacrificed regularly during both the treatment and recovery periods. Selected tissues were removed, weighed fresh and fixed in formalin, processed, and stained with hematoxylin and eosin. Blood samples and bone marrow smears were also obtained. With the use of enhanced histopathology, a description of the changes in lymphoid tissues and bone marrow was used as a means of assessing the susceptibility, and recovery, of the different lymphoid cell populations over time. A correlation with organ weights, flow cytometry data, and bone marrow cytology was achieved. The administration of chlorambucil in the Hanover Wistar rat provided a useful tool to examine the rate and sequence of changes in the lymphoid organs and bone marrow during treatment with, and the recovery from the effects of, a potent immunosuppressive agent.

show abstract

“…The tier 3 assay used was modified from Saad et al [59]. This flow cytometric method distinguishes between nucleated and nonnucleated cells, based on side scatter and LDS-751 staining.…”

Section: Tier 3 Testsmentioning

confidence: 99%